CD70 Protein (CD27L, TNFSF7 Protein)
Cluster of Differentiation 70 (CD 27 Ligand, Tumor Necrosis Factor ligand superfamily member 7)
CD70 Protein, Recombinant
1. Immobilized mouse CD27 at 2 µg/mL (100 µl/well) can bind human CD70 with a linear range of 78-1250 pg/ml. Measured by its binding ability in a functional ELISA.
2. Immobilized mouse CD27/Fc at 2 µg/mL (100 µl/well) can bind biotinylated human CD70 with a linear range of 0.39-12.5 ng/ml. Measured by its binding ability in a functional ELISA.
3.Immobilized human CD27/Fc at 2 µg/mL (100 µl/well) can bind biotinylated human CD70 with a linear range of 0.39-12.5 ng/ml. Measured by its binding ability in a functional ELISA.
CD70 cDNA Clone
CD70 Related Areas
Immunology>>Adaptive Immunity>>Costimulation & Costimulatory Molecule>>CD70/CD27L/TNFSF7
Immunology>>Cytokine & Receptor>>TNF Superfamily>>CD70/CD27L/TNFSF7
Immunology>>Cluster of Differentiation>>B Cell CD Antigen>>CD70/CD27L/TNFSF7
Immunology>>Cluster of Differentiation>>Monocyte/Macrophage CD Antigen>>Other>>CD70/CD27L/TNFSF7
Immunology>>Cluster of Differentiation>>T Cell CD Antigen>>Helper T Cells>>CD70/CD27L/TNFSF7
CD70 Alternative Names
CD70, CD27L, TNFSF7, CD27LG
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.
CD70 Related Studies
- Adam PJ, et al. (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer. 95(3): 298-306.
- Keller AM, et al. (2007) Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proc Natl Acad Sci U S A. 104(14): 5989-94.
- Grewal IS. (2008) CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 12(3): 341-51.
- Boursalian TE, et al. (2009) Targeting CD70 for human therapeutic use. Adv Exp Med Biol. 647: 108-19.
TNF Superfamily Ligands
TNF Receptor Superfamily